Post Covid-19 Conditions after Dehospitalization according to Therapy |Biomedgrid

Introduction: SARS-CoV-2 is the name of the zoonosis caused a new disease, called COVID-19. The long persistence of complaints after the initial infection is called “Post-Acute Consequences of SARS-CoV-2 Infection” (PASC). Purpose: The current prospective study was undertaken to determine whether in-hospital and post-discharge intake of three different molecules: Hydroxychloroquine (HCQ), Rosuvastatin and Melatonin leads to a reduction in complaints, the incidence of new complaints and new hospitalizations during follow-up of patients with severe COVID-19 requiring hospital treatment. Results: We enrolled prospectively 260 patients hospitalized for COVID-19 and us followed-up 73 of them for one month after discharge. The primary endpoint was the occurrence of PASC and whether this was relevant to the therapy being administered. The effect of three different molecules: HCQ (600 mg / day), Rosuvastatin (20 mg / day) and Melatonin (3 mg / day) was compared. For 65 of the followed-up patients we had data about the persistence of symptoms. Of the 26 patients treated with HCQ one month after discharge from hospital, 4 (15.4%) had persistent complaints, compared to the group of 39 patients not receiving HCQ, in which 18 (46.2%) reported complaints (p = 0.010). Patients taking HCQ had also numerically lower rate of the appearance of new complaints and new hospitalizations, but there was no statistically significant difference between the groups. Conclusion: HCQ therapy during hospitalization, despite its benefits to the in-hospital course, demonstrated positive effects on Post COVID-19 conditions only when continued for at least one month after discharge at 200 mg tid/ dose. The observed parameters did not show a statistically significant difference in the two groups with / or without Rosustatin and with / or without Melatonin.